Stockscreener 앱 받기
6.19
1.90%
-0.12
Niagen Bioscience Inc 주식(NAGE)의 최신 뉴스
Will Niagen Bioscience Inc outperform its industry peers2025 Price Action Summary & Growth Focused Entry Reports - baoquankhu1.vn
Exit Recap: What is the Moat Score of Niagen Bioscience IncBond Market & Community Consensus Stock Picks - baoquankhu1.vn
Can Niagen Bioscience’s (NAGE) HSA Access Shift Redefine Its Direct-to-Consumer Growth Strategy? - Yahoo Finance
Revenue Check: Is now the right time to enter Niagen Bioscience IncTrade Exit Summary & Accurate Trade Setup Notifications - baoquankhu1.vn
Niagen Bioscience now allows HSA/FSA payments for Tru Niagen By Investing.com - Investing.com Nigeria
NAGE: Niagen Bioscience advances NAD health solutions, expanding into IV, telehealth, and skincare - TradingView — Track All Markets
Niagen Bioscience (NAGE) Valuation In Focus As Investor Summit Appearance Nears - Yahoo Finance
Niagen Bioscience Expands HSA/FSA Access for Tru Niagen®, the Leading NAD+ Supplement in the U.S. - morningsun.net
Niagen Bioscience now allows HSA/FSA payments for Tru Niagen - Investing.com
Niagen Bioscience Expands HSA/FSA Access for Tru Niagen®, the Leading NAD+ Supplement in the U.S.* - New Castle News
Is Niagen Bioscience (NAGE) Using Investor Summits To Recast Its Healthy Aging Strategy Narrative? - simplywall.st
Insider Buy: Whats the beta of Niagen Bioscience Inc stockEarnings Growth Summary & Fast Momentum Entry Tips - baoquankhu1.vn
Will Weakness in Niagen Bioscience, Inc.'s (NASDAQ:NAGE) Stock Prove Temporary Given Strong Fundamentals? - Yahoo Finance
Is Niagen Bioscience Inc. stock resilient to inflationMarket Growth Report & Entry and Exit Point Strategies - Улправда
Niagen Bioscience, Inc. (NAGE) Stock Analysis: 140.85% Upside Potential Captures Investor Attention - DirectorsTalk Interviews
Published on: 2026-01-08 21:02:30 - Улправда
Will Niagen Bioscience Inc. stock benefit from sector rotationWeekly Profit Report & Fast Momentum Stock Entry Tips - ulpravda.ru
Will Niagen Bioscience Inc. stock deliver shareholder valueJuly 2025 Momentum & Consistent Return Strategy Ideas - Улправда
Why Niagen Bioscience Inc. stock attracts global investorsJuly 2025 Gainers & Smart Swing Trading Alerts - Улправда
Published on: 2026-01-09 00:19:58 - Улправда
Should I hold or sell Niagen Bioscience Inc. stock in 20252025 Bull vs Bear & Weekly High Potential Alerts - ulpravda.ru
Niagen Bioscience: Why Discipline Matters In A Crowded Supplement Market (NASDAQ:NAGE) - Seeking Alpha
Niagen Bioscience, Inc. (NASDAQ:NAGE) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Niagen Bioscience, Inc. (NASDAQ:NAGE) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
What date does Niagen Bioscience, Inc.'s (NAGE) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
Precision Wealth Strategies LLC Makes New $1.53 Million Investment in Niagen Bioscience, Inc. $NAGE - MarketBeat
BSW Wealth Partners Takes Position in Niagen Bioscience, Inc. $NAGE - Defense World
Niagen Bioscience acquires existing nicotinamide riboside patent portfolio - MSN
Niagen Bioscience acquires patent portfolio from Queen’s University Belfast By Investing.com - Investing.com Nigeria
Niagen's ChromaDex Acquires Nicotinamide Riboside Patents From Queen's University Belfast - marketscreener.com
Niagen Bioscience Acquires Existing Core Nicotinamide Riboside (NR) Patent Portfolio from Queen’s University Belfast - PharmiWeb.com
Niagen Bioscience (NAGE) Secures Key Patents, Boosts Revenue For - GuruFocus
Niagen Bioscience acquires patent portfolio from Queen’s University Belfast - Investing.com
Niagen Bioscience (NAGE) Secures Exclusive Ownership of Key Pate - GuruFocus
Niagen Bioscience Secures Full Ownership of Key NR Patents - TipRanks
Niagen Bioscience secures full ownership of key NR patents - MSN
Niagen Bioscience acquires existing core nicotinamide riboside patent portfolio from Queen's University Belfast - marketscreener.com
Niagen Bioscience Signs Patent Assignment Agreement With Queen's University Belfast - TradingView — Track All Markets
Niagen Bioscience (NAGE) secures full patent rights via new QUB deal - Stock Titan
Niagen Bioscience (STU:OCD1) EV-to-OCF : 19.90 (As of Dec. 22, 2025) - GuruFocus
Niagen Bioscience (STU:OCD1) EV-to-FCF : 20.14 (As of Dec. 22, 2025) - GuruFocus
Niagen Bioscience (FRA:OCD1) EV-to-OCF : 19.90 (As of Dec. 21, 2025) - GuruFocus
Market Outlook: Should I hold or sell Niagen Bioscience Inc. stock in 20252025 EndofYear Setup & Daily Profit Focused Screening - ulpravda.ru
Is Niagen Bioscience Inc. stock a safe buy before earningsWatch List & High Accuracy Buy Signal Tips - Улправда
Why Niagen Bioscience Inc. (OCD1) stock stays undervaluedPortfolio Profit Report & Precise Entry and Exit Recommendations - Улправда
Why Niagen Bioscience Inc. stock could see breakout soonStop Loss & AI Based Trade Execution Alerts - Улправда
Volume Recap: Why Niagen Bioscience Inc. (OCD1) stock stays undervalued2025 Market WrapUp & Free Expert Verified Stock Movement Alerts - Улправда
Can Niagen Bioscience Inc. stock outperform in 2025 bull market2025 Stock Rankings & Smart Allocation Stock Tips - DonanımHaber
Published on: 2025-12-19 14:46:11 - DonanımHaber
Will Niagen Bioscience Inc. stock deliver better than expected guidanceJuly 2025 Short Interest & Expert Curated Trade Setups - Улправда
Is Niagen Bioscience Inc. stock vulnerable to regulatory risksQuarterly Investment Review & Free High Return Stock Watch Alerts - Улправда
How strong is Niagen Bioscience Inc. stock balance sheetWeekly Gains Summary & Long-Term Safe Investment Ideas - Улправда
Investors in Niagen Bioscience (NASDAQ:NAGE) have seen incredible returns of 320% over the past three years - Yahoo Finance
Niagen Bioscience (NAGE) Surpasses Q3 Earnings and Revenue Estimates - MSN
Trade Recap: Is Niagen Bioscience Inc stock a smart buy before Fed meeting2025 Market Overview & Daily Market Momentum Tracking - moha.gov.vn
Niagen Bioscience Announces $10 Million Share Buyback - MSN
Niagen Bioscience, Inc. (NASDAQ:NAGE) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Niagen Bioscience, Inc. (NASDAQ:NAGE) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
4.73%
0.92%
자본화:
|
볼륨(24시간):